Crossmark

Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12916-022-02444-8

Published Online: 2022-07-29

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Juan

Bao, Minwei

Gao, Guanghui

Cai, Yiran

Wu, Lihong

Lei, Lei

Zhao, Jing

Ji, Xianxiu

Huang, Ying

Su, Chunxia
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81874036, 82072568)

Science and Technology Commission of Shanghai Municipality (19411971100)

Shanghai Shenkang development research project (SHDC12020110)
License Information

Text and Data Mining valid from 2022-07-29

Version of Record valid from 2022-07-29
More Information

Article History

Received: 2 March 2022

Accepted: 17 June 2022

First Online: 29 July 2022

Declarations

:

: The study was approved by ethics review board at Shanghai Pulmonary Hospital with reference number L21-320 and was performed in accordance with the Declaration of Helsinki. At the time of sample collection, all participants provided written informed consents. The use of all samples in this study was also approved by International Cooperative Scientific Research on Human Genetic Resources (HGR) in China with reference number of 2021SQGH11583.

: Written informed consent for publication was obtained.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below